RxDoctor Payments Data

Anthony Altino, MD

Internal Medicine · Orlando, FLNPI 1477539880

Payments from drug & device makers

$3,016in general payments, 2019–2025

Across 176 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$549
  • Pfizer$404
  • GSK$369
  • Sanofi-aventis U.S. LLC$292
  • Amarin Pharma, Inc.$197
  • Novo Nordisk$196
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,016100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,016 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$16,380
Medicare patients
44
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$114,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$94,315
JanuviaSitagliptin Phosphate61$88,245
OzempicSemaglutide41$50,864
JardianceEmpagliflozin31$40,671
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$23,120
FarxigaDapagliflozin Propanediol17$18,153
TradjentaLinagliptin16$11,861
XareltoRivaroxaban14$11,243
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,786
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$8,752
SymbicortBudesonide/Formoterol Fumarate17$7,983
Albuterol Sulfate HfaAlbuterol Sulfate197$7,729
VascepaIcosapent Ethyl20$6,825
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$404$114,15797 claims
GSKTrelegy Ellipta$369$94,31587 claims
MerckJanuvia$19$88,24561 claims
Boehringer IngelheimJardiance, Tradjenta$86$52,53247 claims
Novo NordiskOzempic$196$50,86441 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$549$36,92346 claims
Johnson & JohnsonXarelto$66$11,24314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →